Background: Osteoporosis is one of the most common conditions associated with aging. It is based on an excess of bone resorption over bone formation, leading to an imbalance of bone turnover. The receptor activator of nuclear factor kappaB ligand (RANKL) is an important regulator of bone metabolism.
Objective: The aim of this investigation was to evaluate potential age- and gender-related changes in free RANKL and total RANKL (free RANKL+RANKL/osteoprotegerin complexes).
Methods: Two hundred and forty volunteers with a median age of 48 years were included in the study. Serum levels of free RANKL and total RANKL were evaluated.
Results: On average, men have a 1.77-fold higher free RANKL level and a 2.12-fold higher free/total RANKL ratio than women of the same age. On average, the RANKL levels decrease by approximately 13% every five years.
Conclusion: This study showed that serum levels of free RANKL and total RANKL decrease with age, and also revealed some gender-related differences.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-2007-993142 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
LGR4 is a key regulator of hepatic gluconeogenesis.
Free Radic Biol Med
January 2025
Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address:
Aims/hypothesis: Emerging evidence underscored the significance of leucine-rich repeat-containing G protein-coupled receptor (LGR) 4 in endocrine and metabolic disorders. Despite this, its role in LGR4 in hepatic glucose metabolism remains poorly understood. In this study we set out to test whether LGR4 regulates glucose production in liver through a specific signaling pathway.
View Article and Find Full Text PDFRANK/RANKL Signaling Pathway in Breast Development and Cancer.
Adv Exp Med Biol
January 2025
Molecular Oncology, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
RANK pathway has attracted increasing interest as a promising target in breast cancer, given the availability of denosumab, an anti-RANKL drug. RANK signaling mediates progesterone-driven regulation of mammary gland development and favors breast cancer initiation by controlling mammary cell proliferation and stem cell fate. RANK activation promotes luminal mammary epithelial cell senescence, acting as an initial barrier to tumorigenesis but ultimately facilitating tumor progression and metastasis.
View Article and Find Full Text PDFRole of Cathepsin K in bone invasion of pituitary adenomas: A dual mechanism involving cell proliferation and osteoclastogenesis.
Cancer Lett
January 2025
Department of Endocrinology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China. Electronic address:
This study aimed to investigate the regulation and underlying mechanism of Cathepsin K (CTSK) in bone-invasive pituitary adenomas (BIPAs). A total of 1437 patients with pituitary adenomas were included and followed up. RNA sequencing, immunohistochemistry, and qRT-PCR were used to analyze CTSK expression.
View Article and Find Full Text PDFMapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect.
Bone Res
October 2024
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Denosumab is a monoclonal anti-RANKL antibody that inhibits bone resorption, increases bone mass, and reduces fracture risk. Denosumab discontinuation causes an extensive wave of rebound resorption, but the cellular mechanisms remain poorly characterized. We utilized in situ hybridization (ISH) as a direct approach to identify the cells that activate osteoclastogenesis through the RANKL/OPG pathway.
View Article and Find Full Text PDFEuropium-Containing Nanospheres for Treating Ovariectomy-Induced Osteoporosis: Targeted Bone Remodeling and Macrophage Polarization Modulation.
Int J Nanomedicine
October 2024
Department of Biomedical Engineering, National Yang Ming Chiao Tung University, Taipei, 112304, Taiwan.
Article Synopsis
- Osteoporosis presents a major health issue characterized by weakened bones, and traditional treatments often have undesirable side effects.
- This study introduces a new treatment method using europium-doped superparamagnetic iron oxide nanocrystals encapsulated in PLGA to promote bone health by altering immune cell behavior and supporting bone-building cells.
- In experiments with lab rats, these nanospheres were shown to effectively reduce bone loss by improving bone cell functions and targeting bone areas using magnetic guidance, significantly enhancing osteoporosis management.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!